Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft certificate-of-analysis minimum data standard — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-003/3
Series
Public comment period
Version
1.0
Published
12 Dec 2023
Last reviewed
12 Dec 2023
Next review
12 Dec 2024
Identifier
10.71829/cei.cp.3
Certainty
Not rated
Cycle
2023 Q4
Window
11 Oct 2023 – 08 Nov 2023
Status
Closed
Submissions
13

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-COA-MINIMUM-/007Dr Fenella LavrentievThe document set should be published in translationNot accepted
DRAFT-COA-MINIMUM-/009Dr Quintus RautavaaraNothing requires a laboratory to demonstrate ongoing performanceAccepted in part
DRAFT-COA-MINIMUM-/012Nkechi Larsson-EkwuemeThe search date is not on the face of the documentAccepted
DRAFT-COA-MINIMUM-/008Ludmila BrackenridgeThe standard would be applied more consistently with a worked exampleAccepted
DRAFT-COA-MINIMUM-/010Dr Gervase CrickhowellNothing in the standard addresses transfer of the method between laboratoriesAccepted in part
DRAFT-COA-MINIMUM-/004Zdenka XimenesResults are reported without an estimate of measurement uncertaintyAccepted in part
DRAFT-COA-MINIMUM-/003Dr Kamila Glendinning-UcheQuantitative claims are reproduced without the method that produced themAccepted
DRAFT-COA-MINIMUM-/005Dr Hamish Nyquist-ObioraReferences should carry a persistent identifier for every cited sourceAccepted in part
DRAFT-COA-MINIMUM-/006Dr Marisol Dunmore-EkpoThe standard does not say what to do with a result outside the expected rangeAccepted
DRAFT-COA-MINIMUM-/011Vittoria QuintanilhaAcceptance criteria are expressed in terms specific to one instrument familyAccepted in part
DRAFT-COA-MINIMUM-/013Dr Ndidi Ravensworth-IlungaAbsence of evidence is presented in a form a reader will take as negative evidenceAccepted
DRAFT-COA-MINIMUM-/001Dr Matthias Whitmarsh-ObiTerms are used in senses that differ from established pharmacopoeial usageAccepted
DRAFT-COA-MINIMUM-/002Dr Wilhelmina WintringhamThe limitations section states what the method cannot do but not what a reader will wrongly concludeAccepted
13 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted7The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part5Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment0The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted1The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Nothing requires a laboratory to demonstrate ongoing performance — arising from DRAFT-COA-MINIMUM-/009. The standard now requires that system suitability results be trended across runs and that a determination report whether the trend was within the laboratory's stated limits, which places the demonstration inside the document the Institute can read.
  2. The search date is not on the face of the document — arising from DRAFT-COA-MINIMUM-/012. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
  3. The standard would be applied more consistently with a worked example — arising from DRAFT-COA-MINIMUM-/008. A worked example is added showing the same primary data treated two ways, with both resulting figures stated and the difference between them quantified, so that the consequence of the misapplication is visible rather than described.
  4. Nothing in the standard addresses transfer of the method between laboratories — arising from DRAFT-COA-MINIMUM-/010. The standard now states the maximum difference between laboratories analysing the same sample at which results are treated as agreeing, and requires that a comparison across laboratories state whether that criterion was met.
  5. Results are reported without an estimate of measurement uncertainty — arising from DRAFT-COA-MINIMUM-/004. Every determination now reports the repeatability observed in the run, the reporting precision, and a statement that two results differing by less than the stated repeatability are not distinguishable by this method.
  6. Quantitative claims are reproduced without the method that produced them — arising from DRAFT-COA-MINIMUM-/003. Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.
  7. References should carry a persistent identifier for every cited source — arising from DRAFT-COA-MINIMUM-/005. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
  8. The standard does not say what to do with a result outside the expected range — arising from DRAFT-COA-MINIMUM-/006. The standard now requires that every determination performed on a sample be reported, that a repeat be permitted only where an assignable cause is documented, and that the assignable cause be stated on the face of the report.
  9. Acceptance criteria are expressed in terms specific to one instrument family — arising from DRAFT-COA-MINIMUM-/011. The acceptance criteria are now expressed in instrument-independent quantities, with the conversion from the common manufacturer-specific reporting units given in a note so that a laboratory can check conformance without recalculating by hand.
  10. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-COA-MINIMUM-/013. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
  11. Terms are used in senses that differ from established pharmacopoeial usage — arising from DRAFT-COA-MINIMUM-/001. The three terms now follow established pharmacopoeial usage, the glossary records the definition and its source, and where the Institute uses a term in a narrower sense the departure is stated at first use in the standard.
  12. The limitations section states what the method cannot do but not what a reader will wrongly conclude — arising from DRAFT-COA-MINIMUM-/002. The limitations section now lists the specific conclusions a conformant determination does not support, each stated as a sentence a reader could otherwise have written, and the list is placed before the references rather than in an annex.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.